正在加载公司
Compass Therapeutics, Inc.
CMPX · Nasdaq · ·
下次财报：2026年11月4日
US$1.09-2.2%9月29日 收盘
- 1M
- -54.6%
- 6M
- -78.6%
- 1Y
- -68.9%
CMPX · Nasdaq · ·
下次财报：2026年11月4日
US$1.09-2.2%9月29日 收盘
Compass Therapeutics, Inc. 预定于 2026年11月4日发布下一份财报。日期来自 Nasdaq 财报日历，公司有时会调整。
截至 2025年12月31日 的季度，与去年同季度相比。
| 指标 | 截至该日的 3 个月2025年12月31日 | 截至该日的 3 个月2024年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$0.00 | US$0.00 | — |
| 利润 | -US$25.2M | -US$19.9M | -26.52% |
| 每股收益 | -US$0.07 | -US$0.14 | +50.00% |
| 自由现金流 | -US$14.9M | -US$11.8M | -26.05% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Compass Therapeutics, Inc. 的业绩电话会文字记录。
“We are increasingly encouraged by the strength and consistency of the tovecimig data as we deepen our analyses ahead of engaging FDA later this month, and we are pleased the full dataset has been selected for an oral presentation at ESMO in October. This enthusiasm is echoed in feedback we’ve received from leading BTC clinicians, which reinforces our belief that tovecimig will be an important treatment option for so many patients with BTC. In the coming weeks, we will be focused on engaging constructively with the FDA and incorporating any feedback as we advance towards a potential BLA filing,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在收盘后或开盘前发布，因此这里的变动是随后的那个交易日。
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Compass Therapeutics, Inc. 于 2026年8月6日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。